

**To:** (10)(2e) [(10)(2e)]@rivm.nl]  
**From:** (10)(2e)@ec.europa.eu  
**Sent:** Fri 5/15/2020 3:36:03 PM  
**Subject:** EU ABS Regulation  
**Received:** Fri 5/15/2020 3:36:08 PM

Dear (10)(2e)

In preparation for our discussions with the Member States concerning Covid 19 and the rules of the EU ABS Regulation, it would help us greatly to know what is actually done with samples of the virus (the question is guided by the fact that not all activities fall in scope of the Regulation). Are the samples used for large scale screening? (I would imagine though that this is done on sequence basis) Are they used to develop a vaccine? Or testing kits? Or merely as a comparison?

Looking forward to your answer

Kind regards,

(10)(2e)



**European Commission**  
Directorate-General for Environment  
Unit ENV F.3 – Multilateral Environmental Cooperation  
Av. de Beaulieu 9 3/176, B-1160 Bruxelles, Belgium  
+32 (10)(2e)